---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-020934"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2026-05-13T11:05:28+00:00"
generated_at: "2026-05-13T11:13:14.355070+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech Q1 net loss $7.3M ($0.13/sh); VERSATILE-003 amended with PFS endpoint

## Summary
- Net loss $7.3M ($0.13 per share) vs $8.5M ($0.21) YoY; revenue not reported.
- R&D expenses $3.5M, down from $5.8M; cash $21.7M at March 31.
- VERSATILE-003 Phase 3 amended to add PFS as interim primary endpoint, reducing enrollment; patients already enrolled continue.
- PDS01ADC mCRC trial: 77.8% ORR and ~85% 24-month survival; mCRPC trial: median PFS 9.6 months.
- New US and Japan patents granted for PDS0101, extending market protection into 2040s.

## SEC filing metadata
- accession: 0001140361-26-020934
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2026-05-13T11:05:28+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036126020934/0001140361-26-020934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036126020934/ef20073195_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-020934
- JSON: https://secwatch.observer/filing/0001140361-26-020934.json
- Plain text: https://secwatch.observer/filing/0001140361-26-020934.txt

## Key facts
- Earnings Releases
  PDS Biotechnology Corp reported the quarter ended March 31, 2026 results: net income net loss of approximately $7.3 million, EPS $0.13 per basic and diluted share.
  - Period: the quarter ended March 31, 2026
  - Net income: net loss of approximately $7.3 million
  - EPS: $0.13 per basic and diluted share
  - Result: reported results
  source text: Reported net loss for the quarter ended March 31, 2026, was approximately $7.3 million, or $0.13 per basic and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036126020934/0001140361-26-020934-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.